A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation

Boron Neutron Capture Therapy (BNCT) is a tumor cell-selective radiotherapy based on a nuclear reaction that occurs when the isotope boron-10 (<sup>10</sup>B) is radiated by low-energy thermal neutrons or epithermal neutrons, triggering a nuclear fission response and enabling a selective...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alessandro Rondina, Paola Fossa, Alessandro Orro, Luciano Milanesi, Antonella De Palma, Davide Perico, Pier Luigi Mauri, Pasqualina D’Ursi
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Boron Neutron Capture Therapy 4-borono-L-phenylalanine Boron Delivery Antibody strategy docking molecular dynamics Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/17f18813770e4ea0bfacae64a0c26105
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:17f18813770e4ea0bfacae64a0c26105
record_format	dspace
spelling	oai:doaj.org-article:17f18813770e4ea0bfacae64a0c261052021-11-25T17:13:05ZA Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation10.3390/cells101132252073-4409https://doaj.org/article/17f18813770e4ea0bfacae64a0c261052021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/3225https://doaj.org/toc/2073-4409Boron Neutron Capture Therapy (BNCT) is a tumor cell-selective radiotherapy based on a nuclear reaction that occurs when the isotope boron-10 (<sup>10</sup>B) is radiated by low-energy thermal neutrons or epithermal neutrons, triggering a nuclear fission response and enabling a selective administration of irradiation to cells. Hence, we need to create novel delivery agents containing <sup>10</sup>B with high tumor selectivity, but also exhibiting low intrinsic toxicity, fast clearance from normal tissue and blood, and no pharmaceutical effects. In the past, boronated monoclonal antibodies have been proposed using large boron-containing molecules or dendrimers, but with no investigations in relation to maintaining antibody specificity and structural and functional features. This work aims at improving the potential of monoclonal antibodies applied to BNCT therapy, identifying in silico the best native residues suitable to be substituted with a boronated one, carefully evaluating the effect of boronation on the 3D structure of the monoclonal antibody and on its binding affinity. A boronated monoclonal antibody was thus generated for specific <sup>10</sup>B delivery. In this context, we have developed a case study of Boron Delivery Antibody Identification Pipeline, which has been tested on cetuximab. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used in the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer, and head and neck cancer.Alessandro RondinaPaola FossaAlessandro OrroLuciano MilanesiAntonella De PalmaDavide PericoPier Luigi MauriPasqualina D’UrsiMDPI AGarticleBoron Neutron Capture Therapy4-borono-L-phenylalanineBoron Delivery Antibody strategydockingmolecular dynamicsBiology (General)QH301-705.5ENCells, Vol 10, Iss 3225, p 3225 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Boron Neutron Capture Therapy 4-borono-L-phenylalanine Boron Delivery Antibody strategy docking molecular dynamics Biology (General) QH301-705.5
spellingShingle	Boron Neutron Capture Therapy 4-borono-L-phenylalanine Boron Delivery Antibody strategy docking molecular dynamics Biology (General) QH301-705.5 Alessandro Rondina Paola Fossa Alessandro Orro Luciano Milanesi Antonella De Palma Davide Perico Pier Luigi Mauri Pasqualina D’Ursi A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation
description	Boron Neutron Capture Therapy (BNCT) is a tumor cell-selective radiotherapy based on a nuclear reaction that occurs when the isotope boron-10 (<sup>10</sup>B) is radiated by low-energy thermal neutrons or epithermal neutrons, triggering a nuclear fission response and enabling a selective administration of irradiation to cells. Hence, we need to create novel delivery agents containing <sup>10</sup>B with high tumor selectivity, but also exhibiting low intrinsic toxicity, fast clearance from normal tissue and blood, and no pharmaceutical effects. In the past, boronated monoclonal antibodies have been proposed using large boron-containing molecules or dendrimers, but with no investigations in relation to maintaining antibody specificity and structural and functional features. This work aims at improving the potential of monoclonal antibodies applied to BNCT therapy, identifying in silico the best native residues suitable to be substituted with a boronated one, carefully evaluating the effect of boronation on the 3D structure of the monoclonal antibody and on its binding affinity. A boronated monoclonal antibody was thus generated for specific <sup>10</sup>B delivery. In this context, we have developed a case study of Boron Delivery Antibody Identification Pipeline, which has been tested on cetuximab. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used in the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer, and head and neck cancer.
format	article
author	Alessandro Rondina Paola Fossa Alessandro Orro Luciano Milanesi Antonella De Palma Davide Perico Pier Luigi Mauri Pasqualina D’Ursi
author_facet	Alessandro Rondina Paola Fossa Alessandro Orro Luciano Milanesi Antonella De Palma Davide Perico Pier Luigi Mauri Pasqualina D’Ursi
author_sort	Alessandro Rondina
title	A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation
title_short	A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation
title_full	A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation
title_fullStr	A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation
title_full_unstemmed	A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation
title_sort	boron delivery antibody (bda) with boronated specific residues: new perspectives in boron neutron capture therapy from an in silico investigation
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/17f18813770e4ea0bfacae64a0c26105
work_keys_str_mv	AT alessandrorondina aborondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT paolafossa aborondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT alessandroorro aborondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT lucianomilanesi aborondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT antonelladepalma aborondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT davideperico aborondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT pierluigimauri aborondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT pasqualinadursi aborondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT alessandrorondina borondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT paolafossa borondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT alessandroorro borondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT lucianomilanesi borondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT antonelladepalma borondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT davideperico borondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT pierluigimauri borondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation AT pasqualinadursi borondeliveryantibodybdawithboronatedspecificresiduesnewperspectivesinboronneutroncapturetherapyfromaninsilicoinvestigation
_version_	1718412573889527808

A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation

Ejemplares similares